Washington, DC –– This week, U.S. Representatives Young Kim (CA-40), Ami Bera, M.D. (CA-06), and Brian Fitzpatrick (PA-01) introduced the bipartisan Global Alzheimer’s Initiative Now (GAIN) Act (H.R. 10175).
The GAIN Act positions the U.S. as a leader in addressing Alzheimer’s disease and dementia through global cooperation, authorizing U.S. participation in the Davos Alzheimer’s Collaborative (DAC). This public–private–patient partnership is transforming research, prevention, and care worldwide.
Alzheimer’s disease and dementia affect nearly 60 million people globally, with cases projected to exceed 150 million by 2050. These diseases already cost the global economy $1.3 trillion annually, doubling every decade.
The GAIN Act highlights the urgency of U.S. leadership in multilateral health efforts. DAC, which has provided grants for 19 healthcare systems across 12 countries, aims to raise and deploy $700 million to advance solutions and fight Alzheimer’s globally.
“Alzheimer’s disease is the third leading cause of death in older adults in Orange County and seventh leading cause of death worldwide. With more resources dedicated to tackling this global challenge, we can save lives,” said Rep. Kim. “The GAIN Act ensures the United States leads the global effort to combat Alzheimer’s disease and other forms of dementia head-on.”
“Alzheimer’s disease is a global challenge that demands a global response,” said Rep. Bera. “The GAIN Act ensures that the United States leads the charge in building partnerships that accelerate research, improve care, and support families everywhere. By strengthening global cooperation, we can achieve more than any single nation can alone.”
“The alarming rate at which Alzheimer’s disease is inflicting our world’s population requires swift and decisive action,” said Rep. Fitzpatrick. “The introduction of the GAIN Act positions America to spearhead life-saving research and sustainable care worldwide, addressing this devastating disease. As a member of the Congressional Task Force on Alzheimer’s Disease, I will always champion legislation that will lead to better results in combatting this deadly illness; that is why I am proud to co-lead this bill and encourage my colleagues to join in this initiative to foster real change in ending Alzheimer’s.”
The GAIN Act advances U.S. leadership by:
- Driving international collaboration to develop innovative diagnostics, treatments, and care models to combat Alzheimer’s disease and dementia for diverse populations worldwide.
- Promoting equitable solutions in low- and middle-income countries, which account for 70% of Alzheimer’s and dementia cases globally, ensuring these regions receive adequate support and resources.
- Aligning U.S. investments with multilateral initiatives to maximize impact, foster innovation, and ensure equitable burden-sharing among participating nations.
- Strengthening global partnerships to address the financial and social pressures of aging populations, with a focus on sustainable healthcare systems and support for caregivers.
- Accelerating advancements in prevention strategies through international research efforts aimed at reducing the global prevalence of Alzheimer’s disease.
